In-House Radio-Labelling Of 131i-Rituximab In Threatment Of Cd20+ B-Cell Non-Hodgkin’s Lymphoma: A Pioneer Experience In Malaysia
Background Radioimmunotherapy (RIT) is an established treatment modality in Non-Hodgkin’s lymphoma (NHL). The only two commercially available RITs - 90Y-ibritumomab tiuxetan (Zevalin®) is expensive and 131I-tositumomab has been discontinued from commercial production. In resource limited environm...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Conference or Workshop Item |
| Language: | English |
| Published: |
2016
|
| Subjects: | |
| Online Access: | http://ir.unimas.my/id/eprint/12287/3/IN-HOUSE%20RADIO-LABELLING%20OF%20131I-RITUXIMAB%20IN%20THREATMENT%20OF%20CD20%2B%20B-CELL%20NON-HODGKIN%E2%80%99S%20LYMPHOMA.pdf http://ir.unimas.my/id/eprint/12287/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|